News | Atrial Fibrillation | July 12, 2017

Wearable Cardiac Monitors Are Effective for Tracking Atrial Fibrillation Following Ablation

Cardea Solo wearable cardiac monitor eliminates service centers and put control of patient data, analysis in the hands of doctors

Cardiac Insight FDA-approved Cardea Solo wearable ECG monitoring system

July 12, 2017 — Cardiac Insight Inc., a U.S. developer of wearable medical devices and diagnostic software, announced its FDA-approved Cardea Solo ECG monitoring system is available for diagnosing atrial fibrillation (AF or AFib) following cardiac ablation. The company’s cardiac monitoring device supports a recent formal consensus statement by experts from 11 leading international cardiology organizations that recognizes the use of wearable sensing devices in patients who have undergone AFib ablation procedures.

The formal acknowledgement of wearable sensors was one of a series of recommendations for treating the millions of patients who have AF, a common rhythm disorder that increases the risk of heart failure and stroke. The expert consensus statement was collectively developed by the Heart Rhythm Society (HRS), European Heart Rhythm Association, European Cardiac Arrhythmia Society, among several others.

Cardiac ablation is an invasive procedure that is used to eliminate atrial fibrillation. Among its many applications, Cardea Solo is a new, distinctive, cost-effective and timely solution for monitoring the effectiveness and results of atrial fibrillation ablation.

“The societies’ recommendations will advance the treatment of atrial fibrillation, including the use of wearable sensors like Cardea Solo for diagnosing heart rhythm disorders and monitoring patients after atrial fibrillation ablation,” said Robert Hauser, M.D., FACC, FHRS, HRS past-president and senior consulting cardiologist (retired), Minneapolis Heart Institute. “It is vital to detect and treat atrial fibrillation before it causes a stroke or heart failure. Cardea Solo provides the information doctors need in a more timely and cost-effective manner than currently offered by other wearable sensors.”

Cardea Solo is the first and only wearable cardiac sensor to eliminate the need for expensive and time-consuming third-party service centers and puts the control of patient data, analysis and processing in the hands of physicians and their staffs.

The device sensor records ECG data and patient symptoms. The wearable sensor is small, lightweight (approximately the weight of three quarters), lead-less, water-resistant and single-use disposable. Patients can wear Cardea Solo comfortably under their clothing for up to seven days and maintain their normal daily activities. The design and ease-of-use also makes it more likely patients will wear the sensor and capture meaningful data for enhanced evaluation.

For more information: www.cardiacinsightinc.com

Related Content

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...

The study used cadaver hearts that were images with contrast enhanced MRI and the images used to create a 3-D computation model of the electrical activation in the heart and how it was influenced by adenosine and ablation. Find more images in the original article

News | Atrial Fibrillation | October 08, 2020
October 8, 2020 – People who suffer from persistent atrial fibrillation in the heart may find relief from a new treat
The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

News | Atrial Fibrillation | August 04, 2020
August 4, 2020 — Abbott announced the first enrollments in the TactiFlex PAF  investigational device exemption (IDE)
PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking